Genome wide association, epidemiological, and clinical studies have established high
lipoprotein (a)[Lp (a)] as a causal risk factor for atherosclerotic cardiovascular disease …

Abnormal immunological indicators associated with disease severity and mortality in
patients with COVID-19 have been reported in several observational studies. However …

The cytokine release syndrome has been proposed as the driver of inflammation in
coronavirus disease 2019 (COVID-19). However, studies on longitudinal cytokine profiles in …

While the respiratory tract is the primary route of entry for SARS-CoV-2, evidence shows that
the virus also impacts the central nervous system. Intriguingly, case reports have …

Introduction The results of studies of tocilizumab (TCZ) in COVID‐19 are contradictory. Our
study aims to update medical evidence from controlled observational studies and …

Introduction: Tocilizumab and baricitinib are recommended treatment options for COVID-19
patients with hyperinflammatory response; however, there is a lack of systematic review …

Background: Among the several therapeutic options assessed for the treatment of
coronavirus disease 2019 (COVID-19), tocilizumab (TCZ), an antagonist of the interleukine …

Introduction Many immunomodulators have been studied in clinical trials for the treatment of
coronavirus disease 2019 (COVID-19). However, data identifying the most effective and …

We read with high interest the article by Manzo et al.[1] about SARS-CoV-2 triggering
polymyalgia rheumatica (PMR). SARS-CoV-2 triggering giant cell arteritis (GCA) have also …

Introduction In coronavirus disease (COVID-19), inflammation takes center stage, with a
cascade of cytokines released, contributing to both inflammation and lung damage. The …